Total Voting Rights
July 1, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in
accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA")
Disclosure Rules and Transparency Rules, notifies the market of the following:
As at June 30, 2016, the Company's issued ordinary share capital comprised
898,880,989 ordinary shares of 5 pence each with voting rights and a further
7,971,461 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 898,880,989. This
is the figure which should be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries across core therapeutic areas including Hematology, Immunology,
Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine
/ Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an
emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com